Cerivastatin, Sodium Salt

• CAT Number: R002645
• CAS Number: 143201-11-0
• Molecular Formula: C26H33FNO5 • Na
• Molecular Weight: 481.50
• Purity: ≥95%
• Synonyms: (3R,5S,6E)-7-[4-(4-Fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-6-heptenoic Acid Sodium Salt; Rivastatin, Baycol, Lipobay
• Target: Apoptosis
• Storage: -20°C
• IUPAC Name: sodium;(E,3R,5S)-7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-di(propan-2-yl)pyridin-3-yl]-3,5-dihydroxyhept-6-enoate
• InChI: InChI=1S/C26H34FNO5.Na/c1-15(2)25-21(11-10-19(29)12-20(30)13-23(31)32)24(17-6-8-18(27)9-7-17)22(14-33-5)26(28-25)16(3)4;/h6-11,15-16,19-20,29-30H,12-14H2,1-5H3,(H,31,32);/q;+1/p-1/b11-10+;/t19-,20-;/m1./s1
• InChIKey: GPUADMRJQVPIAS-QCVDVZFFSA-M
• SMILES: CC(C)C1=C(C(=C(C(=N1)C(C)C)COC)C2=CC=C(C=C2)F)C=CC(CC(CC(=O)[O-])O)O.[Na+]

Cerivastatin sodium（Cat No.:R002645） is a synthetic lipid-lowering drug that functions as a potent HMG-CoA reductase inhibitor with a Ki of 1.3 nM/L. This enzyme inhibition leads to reduced LDL cholesterol levels. Additionally, Cerivastatin sodium demonstrates anticancer effects by inhibiting the proliferation and invasion of MDA-MB-231 cells, primarily through RhoA inhibition. Its well-tolerated oral activity and ability to target both cholesterol and cancer-related pathways make Cerivastatin sodium a promising candidate for medical applications in treating hypercholesterolemia and certain types of cancers.